| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012375753 |
| P356 | DOI | 10.1023/A:1023789416385 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1023/a:1023789416385 |
| P698 | PubMed publication ID | 12884918 |
| P2093 | author name string | Subrata Sen | |
| Hiroshi Katayama | |||
| William R Brinkley | |||
| P433 | issue | 4 | |
| P304 | page(s) | 451-464 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
| P1476 | title | The Aurora kinases: role in cell transformation and tumorigenesis | |
| P478 | volume | 22 |
| Q38936995 | 1-butyltryptophan inhibits cell proliferation, migration, and invasion through the Akt pathway in human gastric cancer cells |
| Q39852380 | 3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line |
| Q48225584 | A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer |
| Q92210036 | A Novel Polyhalogenated Monoterpene Induces Cell Cycle Arrest and Apoptosis in Breast Cancer Cells |
| Q42174912 | A SUMOylation Motif in Aurora-A: Implications for Spindle Dynamics and Oncogenesis |
| Q34694095 | A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer |
| Q33406722 | A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors |
| Q36726212 | A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors |
| Q48676076 | A role for Aurora C in the chromosomal passenger complex during human preimplantation embryo development. |
| Q40070142 | ASAP is a novel substrate of the oncogenic mitotic kinase Aurora-A: phosphorylation on Ser625 is essential to spindle formation and mitosis |
| Q37256808 | Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation |
| Q80731965 | Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries |
| Q36849233 | Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines |
| Q37657488 | Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors |
| Q46492800 | An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei |
| Q35446906 | Anti-centrosome antibodies in breast cancer are the expression of autoimmunity |
| Q33732173 | Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer |
| Q37442586 | Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases |
| Q34026716 | Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. |
| Q37182702 | Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer |
| Q36715681 | Aurora A kinase (AURKA) in normal and pathological cell division |
| Q24324208 | Aurora B -TACC1 protein complex in cytokinesis |
| Q34621867 | Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. |
| Q36066322 | Aurora B kinase phosphorylates and instigates degradation of p53 |
| Q35168142 | Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. |
| Q33914085 | Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts |
| Q42562915 | Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. |
| Q35210664 | Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents |
| Q26771371 | Aurora-A Kinase as a Promising Therapeutic Target in Cancer |
| Q37725402 | Aurora-A is a novel predictor of poor prognosis in patients with resected lung adenocarcinoma |
| Q40204662 | Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway |
| Q37613047 | Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia |
| Q24319687 | Aurora-A phosphorylates hnRNPK and disrupts its interaction with p53 |
| Q39777040 | Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA |
| Q92577211 | Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality |
| Q36366919 | Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis? |
| Q28771757 | Aurora-C Interactions with Survivin and INCENP Reveal Shared and Distinct Features Compared with Aurora-B Chromosome Passenger Protein Complex |
| Q34361195 | Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells |
| Q25255829 | BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution |
| Q38835387 | Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition. |
| Q46089532 | Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. |
| Q34612981 | Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells |
| Q35309234 | CCAAT/enhancer-binding protein delta mediates tumor necrosis factor alpha-induced Aurora kinase C transcription and promotes genomic instability. |
| Q50067516 | Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder. |
| Q39194457 | Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors. |
| Q28594217 | Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal progenitors |
| Q38998361 | Celecoxib prevents curcumin-induced apoptosis in a hematopoietic cancer cell model. |
| Q35669318 | Cell cycle and no end. |
| Q27011729 | Cell cycle progression by the repression of primary cilia formation in proliferating cells |
| Q53187334 | Cell cycle proteins predict recurrence in stage II and III colon cancer. |
| Q37125352 | Cell cycle-dependent ciliogenesis and cancer |
| Q47069578 | Centrosome maturation and duplication in C. elegans require the coiled-coil protein SPD-2. |
| Q28510913 | Chfr is required for tumor suppression and Aurora A regulation |
| Q36419977 | Chromatin control and cancer-drug discovery: realizing the promise |
| Q82282561 | Chromatin-modifying enzymes as therapeutic targets--Part 2 |
| Q82808128 | Chromatin-modulating agents as epigenetic anticancer drugs--'the die is cast' |
| Q28584840 | Conditional Aurora A deficiency differentially affects early mouse embryo patterning |
| Q33655419 | Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity |
| Q37314768 | Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice |
| Q35679855 | Cytometry of the cell cycle: cycling through history |
| Q36324682 | Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells |
| Q42117867 | Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS |
| Q34264571 | Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. |
| Q35871940 | Dawn of Aurora kinase inhibitors as anticancer drugs |
| Q37280830 | Deregulated Aurora-B induced tetraploidy promotes tumorigenesis |
| Q33597161 | Differential expression of centrosomal proteins at different stages of human glioma |
| Q35873154 | Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer |
| Q27663870 | Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase Inhibitor |
| Q33917530 | Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation |
| Q36205257 | Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma |
| Q28279976 | EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A |
| Q37284242 | EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors |
| Q48218548 | Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies |
| Q35549470 | Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. |
| Q39275975 | Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. |
| Q28572162 | Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats |
| Q35850229 | Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells. |
| Q28545854 | Evaluation of the medicinal herb Graptopetalum paraguayense as a treatment for liver cancer |
| Q28480926 | Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells |
| Q37549806 | FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis |
| Q36426514 | FBXW7 is involved in Aurora B degradation. |
| Q33835928 | FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. |
| Q37880074 | From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma |
| Q28570394 | Gene expression changes are age-dependent and lobe-specific in the brown Norway rat model of prostatic hyperplasia |
| Q33503255 | Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target |
| Q90399054 | Gossypin inhibits gastric cancer growth by direct targeting of AURKA and RSK2 |
| Q37629610 | H3 phosphorylation: dual role in mitosis and interphase |
| Q39113716 | HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions |
| Q40336287 | Histone H1 phosphorylation occurs site-specifically during interphase and mitosis: identification of a novel phosphorylation site on histone H1. |
| Q34322087 | Histone modification enzymes: novel targets for cancer drugs |
| Q35216079 | Histone modifiers in cancer: friends or foes? |
| Q38691865 | Histone modifying enzymes: novel disease biomarkers and assay development |
| Q39641991 | Human embryonic stem cells suffer from centrosomal amplification. |
| Q40335511 | Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage |
| Q39975603 | IK-guided PP2A suppresses Aurora B activity in the interphase of tumor cells |
| Q48149761 | Identification and dynamics of two classes of aurora-like kinases in Arabidopsis and other plants |
| Q39736403 | Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase |
| Q34280950 | Increased Aurora B activity causes continuous disruption of kinetochore-microtubule attachments and spindle instability |
| Q33205727 | Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library |
| Q48135741 | Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. |
| Q35215199 | Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle |
| Q33867046 | Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). |
| Q39052359 | Involvement of caspase-2 activation in aurora kinase inhibitor-induced cell death in axin-expressing L929 cells |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions. |
| Q41826328 | Localization of aurora A and aurora B kinases during interphase: role of the N-terminal domain |
| Q34000582 | Long non-coding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells |
| Q36216225 | Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes |
| Q33836931 | Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property |
| Q35406659 | Mismatch repair system in endometriotic tissue and eutopic endometrium of unaffected women |
| Q42254103 | Mitotic Kinases and p53 Signaling |
| Q33926467 | Mitotic chromosomal instability and cancer: mouse modelling of the human disease. |
| Q38030445 | Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy. |
| Q28571256 | Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity |
| Q36158929 | Molecular aetiology and pathogenesis of basal cell carcinoma |
| Q37611227 | Molecular and cell biology of testicular germ cell tumors |
| Q33227163 | Molecular profiling of platinum resistant ovarian cancer. |
| Q37259845 | Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types. |
| Q37310478 | Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia |
| Q64235452 | Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients |
| Q37461061 | Novel strategies for reversing platinum resistance |
| Q37566645 | Novel targets in esophageal and gastric cancer: beyond antiangiogenesis |
| Q36798731 | Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression |
| Q39240059 | Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells |
| Q34064502 | Overexpression of active Aurora-C kinase results in cell transformation and tumour formation |
| Q53345928 | Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. |
| Q33559116 | Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study |
| Q30424963 | Perturbation of Incenp function impedes anaphase chromatid movements and chromosomal passenger protein flux at centromeres |
| Q38270671 | Pharmacological treatment for uterine leiomyosarcomas |
| Q37735199 | Pharmacotherapy of neuroblastoma |
| Q37401839 | Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors |
| Q42365298 | Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer |
| Q35040346 | Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma |
| Q44629246 | Reduced level of the spindle checkpoint protein BUB1B is associated with aneuploidy in colorectal cancers |
| Q40922875 | Regulation of AURKC expression by CpG island methylation in human cancer cells. |
| Q39188213 | S39, a novel Aurora B kinase inhibitor, shows potent antineoplastic activity in human Hela cervical cancer cell line |
| Q51587602 | Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen. |
| Q33813964 | Squamocin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells |
| Q46522604 | Structure-based design of Aurora A & B inhibitors. |
| Q36930279 | Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo |
| Q39759411 | Synthesis and biological evaluation of novel 1-alkyl-tryptophan analogs as potential antitumor agents |
| Q28594290 | Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality |
| Q36379376 | Targeting Aurora kinases in ovarian cancer |
| Q37840163 | Targeting aneuploid cancer cells |
| Q37398815 | Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. |
| Q40184968 | Targeting aurora kinases as therapy in multiple myeloma |
| Q36332561 | Tetraploidy/aneuploidy and stem cells in cancer promotion: The role of chromosome passenger proteins |
| Q30415154 | The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target |
| Q27930816 | The Set1 methyltransferase opposes Ipl1 aurora kinase functions in chromosome segregation |
| Q35885867 | The centrosome in higher organisms: structure, composition, and duplication |
| Q37254126 | The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome |
| Q36661673 | The mammalian centrosome and its functional significance |
| Q39794961 | The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations |
| Q35834849 | The nuclear epidermal growth factor receptor signaling network and its role in cancer |
| Q39205891 | The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines |
| Q35115300 | The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells |
| Q37167047 | The potential role of Aurora kinase inhibitors in haematological malignancies |
| Q28390036 | The role of cadmium and nickel in estrogen receptor signaling and breast cancer: metalloestrogens or not? |
| Q34505702 | The transcription factor YY1 is a novel substrate for Aurora B kinase at G2/M transition of the cell cycle |
| Q37310991 | Translational up-regulation of Aurora-A in EGFR-overexpressed cancer |
| Q36373227 | Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib) |
| Q34781609 | UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion |
| Q36747293 | USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase |
| Q36703456 | Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins |
| Q33942098 | VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. |
| Q99616873 | Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging |
Search more.